Indo Borax & Chemicals, a leading Indian manufacturer of boron-based chemicals, reported a 16% year-on-year increase in consolidated operating income to Rs 129.29 crore for the first half of FY27, compared with Rs 111.42 crore in the corresponding period last year.

 

The company's adjusted EBITDA climbed 22.9% to Rs 28.09 crore in H1FY27, against Rs 22.85 crore in H1FY26, with the adjusted EBITDA margin improving to 21.7%.

 

However, the company’s consolidated profit after tax (PAT) declined 20.7% to Rs 21 crore from Rs 26.47 crore a year ago. The PAT margin stood at 15.4% during the reporting period.

 

The half-year performance reflects robust growth in operating income and adjusted earnings, even as profitability came under pressure.

 

For the second quarter of FY27, Indo Borax reported consolidated operating income of Rs 58.94 crore, compared with Rs 57.85 crore in Q2FY26.

 

Consolidated EBITDA for the quarter stood at Rs 7.93 crore, while PAT came in at Rs 4.75 crore.

 

EBITDA margins faced pressure during the quarter amid elevated raw material costs, driven by global supply chain challenges.

 

The company's Q2FY27 PAT also factored in expenses of Rs 6.64 crore relating to the acquisition of Kronox Lab Sciences Ltd as a subsidiary.

 

In a significant strategic development, Indo Borax has completed the acquisition of a 64.26% stake in Kronox Lab Sciences Ltd, marking an important step in expanding its business portfolio.

 

Following the acquisition, the company appointed Suresh Kalra as Managing Director and Chief Executive Officer of Kronox Lab Sciences.

 

The company has also secured board approval for the amalgamation of its wholly owned subsidiary, Indoborax Infrastructure Private Ltd, with Indo Borax & Chemicals Ltd. The proposed merger remains subject to the necessary regulatory approvals.

 

The acquisition and proposed amalgamation signal the company's push towards strengthening its corporate structure and expanding its growth platform.